Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial

OBJECTIVE: Somapacitan is a reversible albumin-binding growth hormone (GH) derivative, developed for once-weekly administration. This study aimed to evaluate the safety of once-weekly somapacitan vs once-daily Norditropin(®). Local tolerability and treatment satisfaction were also assessed. DESIGN:...

Descripción completa

Detalles Bibliográficos
Autores principales: Johannsson, Gudmundur, Feldt-Rasmussen, Ulla, Håkonsson, Ida Holme, Biering, Henrik, Rodien, Patrice, Tahara, Shigeyuki, Toogood, Andrew, Rasmussen, Michael Højby, Karges, Wolfram, Mann, Alexander, Christiansen, Jens Sandahl, Hansen, Troels Krarup, Andersen, Marianne, Borresen, Sine, Borson-Chazot, Françoise, Kerlan, Véronique, Cariou, Bertrand, Verges, Bruno, Matsuno, Akira, Takano, Koji, Tagami, Tetsuya, Takahashi, Yutaka, Takahashi, Toshikazu, Yamamoto, Masahiro, Höybye, Charlotte, Erfurth, Eva-Marie, Drake, William, Higham, Claire, Murray, Robert, Brooke, Antonia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2018
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5920019/
https://www.ncbi.nlm.nih.gov/pubmed/29500310
http://dx.doi.org/10.1530/EJE-17-1073

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5920019/
https://www.ncbi.nlm.nih.gov/pubmed/29500310
http://dx.doi.org/10.1530/EJE-17-1073

Ejemplares similares